Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

39 results
Display

Gemcitabine and Erlotinib with or without Oxaliplatin in Previously Untreated Advanced Pancreatic Cancer: A Randomized Phase II Trial

Lim SH, Yun J, Lee MY, Kim HJ, Kim KH, Kim SH, Lee SC, Bae SB, Kim CK, Lee N, Lee KT, Park SK, Lee YN, Moon JH

Purpose: Erlotinib has been the only targeted agent to show significantly improved outcomes in pancreatic adenocarcinoma when combined with gemcitabine. We aimed to evaluate whether the addition of oxaliplatin to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients

Choi Y, Keam B, Kim M, Yoon S, Kim D, Choi JG, Seo JY, Park I, Lee JL

PURPOSE: Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a rare genetic syndrome resulting from germline mutations in fumarate hydratase. The combination of bevacizumab plus erlotinib showed promising interim results...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Risk of Herpes Zoster in Patients with Non-small Cell Lung Cancer according to Chemotherapy Regimens: Tyrosine Kinase Inhibitors versus Cytotoxic Chemotherapy

Choi JY, Kim M, Keam B, Kim TM, Kim DW, Heo DS, Jo SJ

PURPOSE: Despite the successful use of tyrosine kinase inhibitors (TKIs) in cancer patients, their effect on herpes zoster development has not been studied. The aim of this study was to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Erlotinib-related Severe Hair Loss with Severe Exanthematous Drug Eruption: A Case Report

Kang JN, Kim DH, Park SH, Seol JE, Kim H

  • KMID: 2436653
  • Korean J Dermatol.
  • 2018 Feb;56(2):139-142.
Erlotinib inhibits the epidermal growth factor receptor and is used in patients with various cancers. However, it can affect the epidermis and hair because the receptor is expressed in normal...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
PET Imaging-Based Phenotyping as a Predictive Biomarker of Response to Tyrosine Kinase Inhibitor Therapy in Non-small Cell Lung Cancer: Are We There Yet?

Gerbaudo V, Kim CK

The increased understanding of the molecular pathology of different malignancies, especially lung cancer, has directed investigational efforts to center on the identification of different molecular targets and on the development...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Concomitant Statin Use Has a Favorable Effect on Gemcitabine-Erlotinib Combination Chemotherapy for Advanced Pancreatic Cancer

Moon DC, Lee HS, Lee YI, Chung MJ, Park JY, Park SW, Song SY, Chung JB, Bang S

PURPOSE: Erlotinib-gemcitabine combined chemotherapy is considered as the standard treatment for unresectable pancreatic cancer. This study aimed to determine the clinical factors associated with response to this treatment. MATERIALS AND METHODS:...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Pneumatosis Cystoides Intestinalis after Erlotinib-containing Chemotherapy for Pancreatic Cancer

Kim GY, Kim MK, Lee DW, Han J, Kim HG

Pneumatosis cystoides intestinalis (PCI) is an uncommon condition that is characterized by the presence of gas within the bowel wall. We experienced a case of PCI after erlotinib-containing chemotherapy for...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for patient with leptomeningeal metastasis of epidermal growth factor receptor mutant non-small cell lung cancer

Lee JS, Lee KA, Lee KH, Moon SY, Kim IA, Jeon SJ, Min JK, Kim HJ, Lee KY

We report on a 64-year-old man with leptomeningeal metastasis (LM) from an epidermal growth factor receptor (EGFR)-mutated adenocarcinoma of the lung. He was treated with paclitaxel, cisplatin. After completion of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Successful Treatment with Empirical Erlotinib in a Patient with Respiratory Failure Caused by Extensive Lung Adenocarcinoma

Jeong SH, Um SW, Lee H, Jeon K, Lee KJ, Suh GY, Chung MP, Kim H, Kwon OJ, Choi YL

We herein describe a 70-year-old woman who presented with respiratory failure due to extensive lung adenocarcinoma. Despite advanced disease, care in the intensive care unit with ventilator support was performed...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer

Lim JY, Cho JH, Lee SJ, Lee DK, Yoon DS, Cho JY

PURPOSE: The purpose of this study is to retrospectively compare the efficacy and tolerability between three regimens for first-line chemotherapy-gemcitabine plus capecitabine (GEM-X), gemcitabine plus erlotinib (GEM-T), and gemcitabine monotherapy...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Ovarian Metastasis from Non-Small Cell Lung Cancer Responding to Erlotinib

Jung IJ, Lim ST, Choi YS, Jang TS, Oh SH, Lee JA, Cho DY

Ovarian cancer is generally primary cancer and less frequently originates from metastasis from non-gynecological cancer. Ovarian metastasis from lung cancer represents only 2~4% of all ovarian metastatic cancers. We report...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure

Cho KM, Keam B, Kim TM, Lee SH, Kim DW, Heo DS

BACKGROUND/AIMS: The purpose of this study was to identify predictive factors for erlotinib treatment in non-small cell lung cancer (NSCLC) patients following gefitinib failure. METHODS: Forty-five patients with NSCLC who were...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Pemetrexed-Erlotinib, Pemetrexed Alone, or Erlotinib Alone as Second-Line Treatment for East Asian and Non-East Asian Never-Smokers with Locally Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer: Exploratory Subgroup Analysis of a Phase II Trial

Lee DH, Lee JS, Wang J, Hsia TC, Wang X, Kim J, Orlando M

PURPOSE: This subgroup analysis of a phase II trial was conducted to assess possible ethnicity-based trends in efficacy and safety in East Asian (EA) and non-EA populations with nonsquamous non-small...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Chemotherapy and Targeted Therapy with Management of Related Complications in Pancreatic Cancer

Lee KH

Prognosis of pancreatic ductal adenocarcinoma is exceptionally poor because timely diagnosis in resectable stages is rare and there is no curative treatment for unresectable cases. Numerous researches to overcome these...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Favorable Treatment Response of Erlotinib in Lung Adenocarcinoma with Concomitant Activating EGFR Mutation and ROS1 Rearrangement

Kim MH, Park Y, Park HJ, Ji AY, Song C, Jin MN, Kim YJ, Kim SW, Lee JH, Kim IS, Kim HR, Kim J, Cho BC

The rearrangement of c-ros oncogene 1 (ROS1) has been recently identified as an important molecular target in non small cell lung cancer (NSCLC). ROS1 rearrangement and epidermal growth factor receptor...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Transformation into large-cell neuroendocrine carcinoma associated with acquired resistance to erlotinib in nonsmall cell lung cancer

Lim JU, Woo IS, Jung YH, Byeon JH, Park CK, Kim TJ, Kim HR

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Phase II Trial of Erlotinib Plus Gemcitabine Chemotherapy in Korean Patients with Advanced Pancreatic Cancer and Prognostic Factors for Chemotherapeutic Response

Park S, Chung MJ, Park JY, Chung JB, Bang S, Park SW, Song SY

  • KMID: 1806680
  • Gut Liver.
  • 2013 Sep;7(5):611-615.
BACKGROUND/AIMS: Erlotinib and gemcitabine combined chemotherapy is becoming the treatment of choice in advanced pancreatic cancer. We evaluated the effectiveness of treatment with erlotinib plus gemcitabine and the prognostic factors...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Bioequivalence of Two Erlotinib Formulations in Healthy Volunteers

Kim J, Jin EH, Choi YW, Min BG, Lee BH, Chung JS, Nam KY, Jung WT, Kim SH, Lee HJ, Hong JH

BACKGROUND: Erlotinib is a tyrosine kinase inhibitor prescribed for the treatment of non-small cell lung cancer and pancreatic cancer. The aim of this study was to compare the safety and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Erlotinib Induced Trichomegaly of the Eyelashes

Jeon SH, Ryu JS, Choi GS, Kim JS, Kwon HY, Kim MS, Nam HS, Cho JH, Kwak SM, Lee HL, Kim HJ, Hong GJ

  • KMID: 2320233
  • Tuberc Respir Dis.
  • 2013 Jan;74(1):37-40.
Epithelial growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been widely used for non-small-cell lung cancer patients. Its untoward cutaneous effects are largely well known and developed in many...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison of Therapeutic Efficacy of Gefitinib and Erlotinib in Patients with Squamous Cell Lung Cancer

Shin HJ, Kim TO, Kang HW, Chi SY, Ban HJ, Kim SO, Kwon YS, Oh IJ, Kim KS, Kim YI, Lim SC, Kim YC

  • KMID: 2319541
  • Tuberc Respir Dis.
  • 2011 Jul;71(1):15-23.
BACKGROUND: Gefitinib and erlotinib are useful, molecular targeted agents in patients with non-small-cell lung cancer (NSCLC) who failed previous chemotherapy. We compared the efficacy and toxicity of two drugs in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr